An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib
- Status
- WITHDRAWN
- Phase
- PHASE2
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
- Status
- UNKNOWN
- Phase
- PHASE2
Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors
- Status
- COMPLETED
- Phase
- NA
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
- Status
- COMPLETED
- Phase
- PHASE1
European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy
- Status
- COMPLETED
- Phase
- NA
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Study of MLN8237 in Participants With Advanced Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Inflammatory Cytokines in Symptom Production in Multiple Myeloma
- Status
- COMPLETED
- Phase
- N/A
Total Marrow Irradiation for Refractory Acute Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
HD Melphalan and SCT in Patients With IGDD or LCDD
- Status
- TERMINATED
- Phase
- PHASE2
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2